Method and compositions for cellular immunotherapy
US10865242B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 8, 2015 |
| Grant date | Dec 15, 2020 |
| Priority date | — |
| Expiry date | Apr 8, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/68
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. In some alternatives, the ligand binding domains binds to CD171.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.